Beigene Ltd (NASDAQ:BGNE) Director Bros. Advisors Lp Baker purchased 1,980,198 shares of the business’s stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average price of $101.00 per share, for a total transaction of $199,999,998.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Shares of Beigene Ltd (NASDAQ:BGNE) opened at $123.76 on Wednesday. The company has a market cap of $5,630.00 and a P/E ratio of -94.47. Beigene Ltd has a one year low of $32.34 and a one year high of $127.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 9.27 and a current ratio of 9.33.

Beigene (NASDAQ:BGNE) last issued its quarterly earnings data on Monday, November 13th. The company reported $2.54 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $2.31. The firm had revenue of $220.21 million for the quarter, compared to analyst estimates of $1.55 million. During the same period in the previous year, the business earned ($1.08) EPS. research analysts forecast that Beigene Ltd will post -2.04 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of BGNE. SG Americas Securities LLC acquired a new stake in shares of Beigene during the 2nd quarter worth approximately $111,000. Quantbot Technologies LP acquired a new stake in Beigene in the 3rd quarter valued at $160,000. Profund Advisors LLC acquired a new stake in Beigene in the 2nd quarter valued at $248,000. Teachers Retirement System of The State of Kentucky acquired a new stake in Beigene in the 3rd quarter valued at $248,000. Finally, Aperio Group LLC acquired a new stake in Beigene in the 3rd quarter valued at $301,000. 55.32% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently weighed in on BGNE shares. Zacks Investment Research upgraded shares of Beigene from a “hold” rating to a “buy” rating and set a $115.00 price target on the stock in a report on Tuesday, October 3rd. Maxim Group reiterated a “buy” rating and issued a $120.00 price target (up previously from $77.00) on shares of Beigene in a report on Thursday, September 28th. BidaskClub upgraded shares of Beigene from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, Cowen reiterated a “buy” rating on shares of Beigene in a report on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. Beigene has a consensus rating of “Hold” and a consensus target price of $96.67.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at

About Beigene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with's FREE daily email newsletter.